NCT03833180View on ClinicalTrials.gov

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

March 14, 2019

Primary Completion Date

December 18, 2023

Study Completion Date

December 18, 2023

Conditions
Chronic Lymphocytic LeukemiaMantle Cell LymphomaFollicular LymphomaMarginal Zone LymphomaDiffuse Large B-cell LymphomaRichter Transformation LymphomaBurkitt LymphomaLymphoplasmacytoid LymphomaT-cell Non-Hodgkin LymphomaAcute Lymphoid LeukemiaAcute Myeloid LeukemiaWaldenstrom Macroglobulinemia
Interventions
DRUG

Zilovertamab vedotin

Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.

Trial Locations (14)

10021

Weill Cornell Medical College ( Site 0005), New York

10065

Memorial Sloan Kettering Cancer Center ( Site 0014), New York

11042

Northwell Health ( Site 0009), New Hyde Park

11553

Memorial Sloan-Kettering Cancer Center ( Site 0019), Uniondale

14642

University of Rochester ( Site 0008), Rochester

22908

University of Virginia Cancer Center ( Site 0012), Charlottesville

77030

MD Anderson Cancer Center ( Site 0001), Houston

MD Anderson Cancer Center ( Site 0011), Houston

90095

UCLA Hematology & Oncology ( Site 0007), Los Angeles

91010

City of Hope ( Site 0010), Duarte

92093

University of California - San Diego ( Site 0003), La Jolla

97239

Oregon Health & Science University ( Site 0004), Portland

98104

Swedish Medical Center ( Site 0002), Seattle

68198-5331

University of Nebraska Medical Center ( Site 0006), Omaha

All Listed Sponsors
lead

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT03833180 - A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | Biotech Hunter | Biotech Hunter